(Make sure your sound is on. This video may take 10 seconds to load)

Prosta Peak is not endorsed by, sponsored by, or affiliated with any of these organizations.

Scientific References

Prosta Peak is not endorsed by, sponsored by, or affiliated with any of these organizations.

  • 1. Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7 Suppl 9(Suppl 9):S3-S14.
  • 2.Abrams P. LUTS, BPH, BPE, BPO: A Plea for the Logical Use of Correct Terms. Rev Urol. 1999 Spring;1(2):65.
  • 3.Silverman WM. "Alphabet soup" and the prostate: LUTS, BPH, BPE, and BOO. J Am Osteopath Assoc. 2004 Feb;104(2 Suppl 2):S1-4.
  • 4.Abrams P. New words for old: lower urinary tract symptoms for "prostatism". BMJ. 1994 Apr 09;308(6934):929-30.
  • 5.Roehrborn CG. Pathology of benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S11-8.
  • 6.Parsons JK. Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. Curr Bladder Dysfunct Rep. 2010 Dec;5(4):212-218.
  • 7.Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016 May 05;2:16031.
  • 8. Schenk JM, Calip GS, Tangen CM, Goodman P, Parsons JK, Thompson IM, Kristal AR. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol. 2012 Jul 15;176(2):156-63.
  • 9.Sutcliffe S, Grubb Iii RL, Platz EA, Ragard LR, Riley TL, Kazin SS, Hayes RB, Hsing AW, Andriole GL., Urologic Diseases in America Project. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. BJU Int. 2012 Oct;110(7):1050-9.
  • 10.Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia. Prostate. 2017 Jun;77(9):1029-1035.
  • 11. Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort. Prostate Cancer Prostatic Dis. 2018 Sep;21(3):373-378.
  • 12.Foster CS. Pathology of benign prostatic hyperplasia. Prostate Suppl. 2000;9:4-14.
  • 13.Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5(5):545-57.
  • 14. Gann PH, Hennekens CH, Longcope C, Verhoek-Oftedahl W, Grodstein F, Stampfer MJ. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate. 1995 Jan;26(1):40-9.
  • 15.Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005 Mar;29(3):310-6.
  • 16.Nygård LH, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ. Antidiabetic drugs, glycemic control and risk of benign prostatic hyperplasia. Prostate. 2023 Feb;83(3):246-258.

Prosta Peak is not endorsed by, sponsored by, or affiliated with any of these organizations.